FogPharma
The AI engine Fit Assessment
BetaFogPharma creates cell-penetrating mini proteins to target and neutralize cancer-causing proteins, offering new precision medicines for cancer treatment beyond conventional methods.
Blurb
FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.
HQ Location
Cambridge (United States)
Founded
2015
Employees
140
Total funding raised
$530.27M
Last Funding Event
Series E, $145.00M, March 1, 2024
Smart insights
- Greg Verdine (Co-Founder, President and CEO) has 12 years of experience in the Healthcare industry at companies such as Third Rock Ventures and Apple Tree Partners
- Greg Verdine (Co-Founder, President and CEO) has 4 years of experience in the Life Sciences industry at Apple Tree Partners
- Greg Verdine (Co-Founder, President and CEO) has 12 years of experience in the Biotechnology industry at companies such as Third Rock Ventures and Apple Tree Partners
- Sandra Smith (Vice President, People) worked at Microsoft as New England Research & Development Site HR Leader for 8.5 years (2011 - 2019)
- Greg Verdine (Co-Founder, President and CEO) holds a PhD, Chemistry from Columbia University in the City of New York (1981 - 1986)
- John McGee (Scientific Founder, Head of De Novo Discovery) holds a BS, Chemistry from Stanford University (2004 - 2008)
- John McGee (Scientific Founder, Head of De Novo Discovery) holds a PhD, Biochemistry from Harvard University (2008 - 2013)
- 6m headcount growth: 4%
- 1Y headcount growth: 9%
- Headcount-to-last-round ratio: 13.6 employees/$M
Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. The company's mini proteins (CPMPs) are a broad new class of medicines that can drug target beyond the reach of conventional therapeutics, enabling physicians to treat cancer-related diseases.